The global Mesenchymal Stem Cells market size is expected to be worth around US$ 8.1 billion by 2030, according to a new report by Vision Research Reports.
The global Mesenchymal Stem Cells market size was valued at US$ 5.4 billion in 2020 and is anticipated to grow at a CAGR of 15.6% during forecast period 2021 to 2030.
Growth Factors
Mesenchymal stem cells (MSCs) are set to gain popularity among healthcare professionals, to develop novel therapeutics, primarily targeted at the treatment of several immune-mediated disorders. MSCs have been acclaimed effective as a regenerative therapy for skeletal tissue repair and have recently gained traction across modulation of immune cells and endogenous tissues.
Expanding clinical applications of mesenchymal stem cells, strengthening the pipeline of these therapies, along with intensifying market competition are some of the key aspects driving the industry expansion of MSCs. The recent pandemic outbreak of COVID-19 is set to propel the clinical applications and investments done in this market space. For instance, in April 2020, Canada’s The Stem Cell Network (SCN) provided funding of USD 300,000 to the project targeted towards the evaluation of optimal dosage of MSCs, to design an effective therapeutic approach to reduce the impacts of respiratory disorders associated with SARS-CoV-2 infection.
Report Highlights
The products segment dominated the market and accounted for the largest revenue share of 80.1% in 2020. Among the products, the cells and cell lines segment has emerged as a key contributor to the segment’s revenue. Several market players are engaged in capturing untapped avenues of this market space by undertaking various initiatives such as new product development, business expansion. These players offer mesenchymal stem cells and cell lines to support the research community.
The kits, media, and reagents segment is expected to register the highest growth rate of 15.4% from 2021 to 2030. Expanding product lines by competitors serves as the key attributive factor to the segment’s fast-paced growth. In March 2020, researchers from China developed a full chemical-defined medium - NBVbe medium that supports the isolation of human MSCs. This new product is expected to aid the optimization of MSC medium, molecular characterization, and clinical applications.
The allogeneic MSCs segment dominated the market and accounted for the largest revenue share of 56.3% in 2020. This is attributed to the high safety profile of allogeneic mesenchymal stem cells in clinical applications. Additionally, implantation of allogeneic MSCs is set to emerge as a pioneering cell-based therapeutic approach owing to the associated low immunogenicity coupled with immunosuppressive properties. These properties result in a reduced immune response, which in turn contributes to the success of allogeneic MSC implantations.
On the other hand, the use of autologous mesenchymal stem cells has undergone various advances in the past few years. The segment is expected to register a CAGR of 15.5% over the forecast period.
The bone marrow segment dominated the market and accounted for the largest revenue share of 28.8% in 2020. Bone marrow is a major source of isolation for mesenchymal stem cells. These cells have multilineage differentiation potential and are able to differentiate into bones, cartilage, tendons, fibroblasts, fat, cardiac muscle cells, and endothelial cells.
MSCs derived from adipose tissues have pegged the second position in the market in terms of revenue share. The segment is expected to register a CAGR of 15.9% over the forecast period. These offer multipotent mesenchymal stem cells exhibiting several advantages across extraction, isolation, and expansion along with robust cell concentration.
The cardiovascular diseases segment dominated the Mesenchymal Stem Cells (MSCs) market and accounted for the largest revenue share of 25.0% in 2020. Several pre-clinical studies have shown that the transplantation of mesenchymal stem cells improves cardiovascular repair, which has strengthened the penetration of MSCs in cardiovascular disease indications.
This has gained significant traction across clinical applications associated with the Graft versus Host Disease (GvHD), contributing to the highest growth rate of 16.4% from 2021 to 2030. In addition, since the last decade, oncology applications of cell therapies have witnessed rapid developments with the MSCs at the forefront.
The disease modelling application segment dominated the market and accounted for the largest revenue share of 39.8% in 2020. The use of cellular disease models with patient-specific MSCs provides an ideal tool for pathological research. The mesenchymal stem cells derived from patient Induced Pluripotent Stem Cells serve as a potential disease modelling tool.
North America dominated the market and accounted for the largest revenue share of 56.1% in 2020. A substantial number of clinical trials are underway to assess the efficacy and safety of mesenchymal stem cells as a viable treatment, for several life-threatening diseases in the U.S.Furthermore, a significant number of major companies that are engaged in the supply and commercialization of MSCs are headquartered in the U.S. These factors have contributed to the dominance of the region in the market.
A strong research base to evaluate the implications of clinical scale manufacturing of mesenchymal stem cells coupled with improved funding programs from various public and private organizations is expected to drive the adoption of MSCs across the European countries. Countries in the Asia Pacific region are expected to create strong competitors in this space.
Report Coverage | Details |
Market Size | US$ 8.1 billion by 2030 |
Growth Rate | CAGR of 15.6% From 2021 to 2030 |
Base Year | 2020 |
Historic Data | 2017 to 2020 |
Forecast Period | 2021 to 2030 |
Segments Covered | Product & Services, Type, Source of Isolation, Indication, Application |
Regional Scope | North America, Europe, APAC, MEA, Latin America |
Companies Mentioned | Thermo Fisher Scientific, Inc., Cell Applications, Inc., Axol Biosciences Ltd., Cytori Therapeutics Inc, STEMCELL Technologies Inc, Cyagen Biosciences Inc., Celprogen Inc, BrainStorm Cell Therapeutics Inc. |
Key Players
Thermo Fisher Scientific, Inc.
Cell Applications, Inc.
Axol Biosciences Ltd.
Cytori Therapeutics Inc
STEMCELL Technologies Inc
Cyagen Biosciences Inc.
Celprogen Inc
BrainStorm Cell Therapeutics Inc.
Stemedica Cell Technologies Inc
Merck KGaA (MilliporeSigma)
Smith+Nephew
Lonza AG
PromoCell GmbH
ScienCell Research Laboratories
American Type Culture Collection
Market Segmentation
Product & Services Outlook
Products
Workflow Type
Cell Sourcing & Isolation
Culture & Cryopreservation
Differentiation
Characterization
Product Type
Cells & Cell Lines
Kits, Media, & Reagents
Others
Services
Type Outlook
Autologous
Allogeneic
Source of Isolation Outlook
Bone Marrow
Cord Blood
Peripheral Blood
Fallopian Tube
Fetal Liver
Lung
Adipose Tissues
Indication Outlook
Bone And Cartilage Repair
Cardiovascular Disease
Inflammatory And Immunological Diseases
Liver Diseases
Cancer
GvHD
Others
Application Outlook
Disease Modelling
Drug Development & Discovery
Stem Cell Banking
Tissue Engineering
Toxicology Studies
Others
Regional Outlook
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Asia Pacific
Japan
China
India
South Korea
Latin America
Brazil
Mexico
Middle East & Africa
South Africa
Saudi Arabia
The Mesenchymal Stem Cells market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Mesenchymal Stem Cells market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Mesenchymal Stem Cells market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Mesenchymal Stem Cells market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Mesenchymal Stem Cells market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Mesenchymal Stem Cells capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Mesenchymal Stem Cells by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Mesenchymal Stem Cells market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Mesenchymal Stem Cells market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Mesenchymal Stem Cells market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Mesenchymal Stem Cells industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
Mesenchymal Stem Cells market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Mesenchymal Stem Cells market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Mesenchymal Stem Cells market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Mesenchymal Stem Cells market. These factors have benefited the growth of the global market for Mesenchymal Stem Cells. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Mesenchymal Stem Cells. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Mesenchymal Stem Cells are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Mesenchymal Stem Cells Market, By Product & Services Type
7.1. Mesenchymal Stem Cells Market, by Product & Services Type, 2021-2030
7.1.1. Products
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Services
7.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Mesenchymal Stem Cells Market, By Product Type
8.1. Mesenchymal Stem Cells Market, by Product Type, 2021-2030
8.1.1. Autologous
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Allogeneic
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Mesenchymal Stem Cells Market, By Source of Isolation Type
9.1. Mesenchymal Stem Cells Market, by Source of Isolation Type, 2021-2030
9.1.1. Bone Marrow
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Cord Blood
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. UV Peripheral Blood
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Fallopian Tube
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Fetal Liver
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Lung
9.1.6.1. Market Revenue and Forecast (2017-2030)
9.1.7. Adipose Tissues
9.1.7.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Mesenchymal Stem Cells Market, By Indication Type
10.1. Mesenchymal Stem Cells Market, by Indication Type, 2021-2030
10.1.1. Bone And Cartilage Repair
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Cardiovascular Disease
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Inflammatory And Immunological Diseases
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Liver Diseases
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Cancer
10.1.5.1. Market Revenue and Forecast (2017-2030)
10.1.6. GvHD
10.1.6.1. Market Revenue and Forecast (2017-2030)
10.1.7. Others
10.1.7.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Mesenchymal Stem Cells Market, By Application Type
11.1. Mesenchymal Stem Cells Market, by Application, 2021-2030
11.1.1. Disease Modelling
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Drug Development & Discovery
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Stem Cell Banking
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Tissue Engineering
11.1.4.1. Market Revenue and Forecast (2017-2030)
11.1.5. Toxicology Studies
11.1.5.1. Market Revenue and Forecast (2017-2030)
11.1.6. Others
11.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Mesenchymal Stem Cells Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.1.2. Market Revenue and Forecast, by Product (2017-2030)
12.1.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.1.4. Market Revenue and Forecast, by Indication (2017-2030)
12.1.5. Market Revenue and Forecast, by Application (2017-2030)
12.1.6. U.S.
12.1.6.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Product (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Indication (2017-2030)
12.1.7. Market Revenue and Forecast, by Application (2017-2030)
12.1.8. Rest of North America
12.1.8.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.1.8.2. Market Revenue and Forecast, by Product (2017-2030)
12.1.8.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.1.8.4. Market Revenue and Forecast, by Indication (2017-2030)
12.1.8.5. Market Revenue and Forecast, by Application (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.2.2. Market Revenue and Forecast, by Product (2017-2030)
12.2.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.2.4. Market Revenue and Forecast, by Indication (2017-2030)
12.2.5. Market Revenue and Forecast, by Application (2017-2030)
12.2.6. UK
12.2.6.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Product (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.2.7. Market Revenue and Forecast, by Indication (2017-2030)
12.2.8. Market Revenue and Forecast, by Application (2017-2030)
12.2.9. Germany
12.2.9.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.2.9.2. Market Revenue and Forecast, by Product (2017-2030)
12.2.9.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.2.10. Market Revenue and Forecast, by Indication (2017-2030)
12.2.11. Market Revenue and Forecast, by Application (2017-2030)
12.2.12. France
12.2.12.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.2.12.2. Market Revenue and Forecast, by Product (2017-2030)
12.2.12.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.2.12.4. Market Revenue and Forecast, by Indication (2017-2030)
12.2.13. Market Revenue and Forecast, by Application (2017-2030)
12.2.14. Rest of Europe
12.2.14.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.2.14.2. Market Revenue and Forecast, by Product (2017-2030)
12.2.14.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.2.14.4. Market Revenue and Forecast, by Indication (2017-2030)
12.2.15. Market Revenue and Forecast, by Application (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.3.2. Market Revenue and Forecast, by Product (2017-2030)
12.3.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.3.4. Market Revenue and Forecast, by Indication (2017-2030)
12.3.5. Market Revenue and Forecast, by Application (2017-2030)
12.3.6. India
12.3.6.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Product (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Indication (2017-2030)
12.3.7. Market Revenue and Forecast, by Application (2017-2030)
12.3.8. China
12.3.8.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Product (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Indication (2017-2030)
12.3.9. Market Revenue and Forecast, by Application (2017-2030)
12.3.10. Japan
12.3.10.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.3.10.2. Market Revenue and Forecast, by Product (2017-2030)
12.3.10.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.3.10.4. Market Revenue and Forecast, by Indication (2017-2030)
12.3.10.5. Market Revenue and Forecast, by Application (2017-2030)
12.3.11. Rest of APAC
12.3.11.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.3.11.2. Market Revenue and Forecast, by Product (2017-2030)
12.3.11.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.3.11.4. Market Revenue and Forecast, by Indication (2017-2030)
12.3.11.5. Market Revenue and Forecast, by Application (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.4.2. Market Revenue and Forecast, by Product (2017-2030)
12.4.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.4.4. Market Revenue and Forecast, by Indication (2017-2030)
12.4.5. Market Revenue and Forecast, by Application (2017-2030)
12.4.6. GCC
12.4.6.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Product (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Indication (2017-2030)
12.4.7. Market Revenue and Forecast, by Application (2017-2030)
12.4.8. North Africa
12.4.8.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Product (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Indication (2017-2030)
12.4.9. Market Revenue and Forecast, by Application (2017-2030)
12.4.10. South Africa
12.4.10.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.4.10.2. Market Revenue and Forecast, by Product (2017-2030)
12.4.10.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.4.10.4. Market Revenue and Forecast, by Indication (2017-2030)
12.4.10.5. Market Revenue and Forecast, by Application (2017-2030)
12.4.11. Rest of MEA
12.4.11.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.4.11.2. Market Revenue and Forecast, by Product (2017-2030)
12.4.11.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.4.11.4. Market Revenue and Forecast, by Indication (2017-2030)
12.4.11.5. Market Revenue and Forecast, by Application (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.5.2. Market Revenue and Forecast, by Product (2017-2030)
12.5.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.5.4. Market Revenue and Forecast, by Indication (2017-2030)
12.5.5. Market Revenue and Forecast, by Application (2017-2030)
12.5.6. Brazil
12.5.6.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Product (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Indication (2017-2030)
12.5.7. Market Revenue and Forecast, by Application (2017-2030)
12.5.8. Rest of LATAM
12.5.8.1. Market Revenue and Forecast, by Product & Services (2017-2030)
12.5.8.2. Market Revenue and Forecast, by Product (2017-2030)
12.5.8.3. Market Revenue and Forecast, by Source of Isolation (2017-2030)
12.5.8.4. Market Revenue and Forecast, by Indication (2017-2030)
12.5.8.5. Market Revenue and Forecast, by Application (2017-2030)
Chapter 13. Company Profiles
13.1. Thermo Fisher Scientific
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Cell Applications, Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Axol Biosciences Ltd.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Cytori Therapeutics Inc
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. STEMCELL Technologies Inc
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Cyagen Biosciences Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Celprogen Inc
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. BrainStorm Cell Therapeutics Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Stemedica Cell Technologies Inc
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Merck KGaA (MilliporeSigma)
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
13.11. Smith+Nephew
13.11.1. Company Overview
13.11.2. Product Offerings
13.11.3. Financial Performance
13.11.4. Recent Initiatives
13.12. Lonza AG
13.12.1. Company Overview
13.12.2. Product Offerings
13.12.3. Financial Performance
13.12.4. Recent Initiatives
13.13. PromoCell GmbH
13.13.1. Company Overview
13.13.2. Product Offerings
13.13.3. Financial Performance
13.13.4. Recent Initiatives
13.14. ScienCell Research Laboratories
13.14.1. Company Overview
13.14.2. Product Offerings
13.14.3. Financial Performance
13.14.4. Recent Initiatives
13.15. American Type Culture Collection
13.15.1. Company Overview
13.15.2. Product Offerings
13.15.3. Financial Performance
13.15.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms